The GM-CSF has been shown to enhance anti-GD2-mediated ADCC by granulocytes in disease-free subjects and in patients with neuroblastoma (Yu et al, 1997; Batova et al, 1999). The gene discussed is CSF2; the disease is neuroblastoma.